Summary
A groundbreaking Phase 2 clinical trial using CRISPR to target aging genes showed significant improvements.
Balanced Perspective
Promising early results, but long-term safety data are still needed.
Optimistic View
We may be witnessing the beginning of the end of age-related disease.
Critical View
Could create massive inequality if anti-aging treatments are only available to the wealthy.
Source
Originally reported by Science Magazine